Oral dehydroepiandrosterone vs placebo
Adverse events: severe · patients with cutaneous disease in systemic lupus erythematosus
Oral dehydroepiandrosterone showed no clear difference in adverse events: severe compared with placebo (moderate certainty).
1 finding from 1 review
- Interventions for cutaneous disease in systemic lupus erythematosus 2021 · Cochrane Headline outcomes onlyRR 0.09 [0.01, 1.66]1 study · 381 participantsModerate